Reamberin
PreclinicalSmall molecule
Reamberin is one of 35 small molecule programs targeting Diabetic Ketoacidosis. It is currently in Preclinical.
2
Indications
4
Total Trials
2
Active Trials
34
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
1931 competitors in COVID-19
#DrugCompanyPhaseTrials
1COVID-19 Vaccine
ModernaPreclinical
Stivarga
BayerPreclinical
Aldactone
PfizerPreclinical
Nexavar
BayerPreclinical
Benadryl
PParkedale
Preclinical
Aprotinin
BayerPreclinical
Antithrombin-III
OctapharmaPreclinical
Blood Taken
HHospices Civils de Lyon
Preclinical
Moderna COVID-19 Vaccine
ModernaPreclinical
C21
VVicore Pharma AB
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Diabetic Ketoacidosis1 trial
REAMBERIN® 1.5% in Rehydration Therapy of Diabetic Ketoacidosis
Recruiting·PPOLYSAN Scientific & Technological Pharmaceutical Company·Phase 2/3·NCT06955416·312 enrolled
COVID-191 trial
Efficacy and Safety1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Reamberin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details